JP2024516172A5 - - Google Patents
Info
- Publication number
- JP2024516172A5 JP2024516172A5 JP2023564582A JP2023564582A JP2024516172A5 JP 2024516172 A5 JP2024516172 A5 JP 2024516172A5 JP 2023564582 A JP2023564582 A JP 2023564582A JP 2023564582 A JP2023564582 A JP 2023564582A JP 2024516172 A5 JP2024516172 A5 JP 2024516172A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- subject
- dose
- mlpscs
- ards
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021901214 | 2021-04-23 | ||
| AU2021901214A AU2021901214A0 (en) | 2021-04-23 | Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells | |
| AU2021902180A AU2021902180A0 (en) | 2021-07-15 | Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells | |
| AU2021902180 | 2021-07-15 | ||
| AU2022900260 | 2022-02-09 | ||
| AU2022900260A AU2022900260A0 (en) | 2022-02-09 | Method for treating acute respiratory distress syndrome (ARDS) in specific patients using mesenchymal lineage precursor or stem cells | |
| AU2022900372A AU2022900372A0 (en) | 2022-02-18 | Method for treating acute respiratory distress syndrome (ARDS) using mesenchymal lineage precursor or stem cells | |
| AU2022900372 | 2022-02-18 | ||
| PCT/IB2022/053763 WO2022224207A1 (en) | 2021-04-23 | 2022-04-22 | Method for treating acute respiratory distress syndrome (ards) using mesenchymal lineage precursor or stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516172A JP2024516172A (ja) | 2024-04-12 |
| JP2024516172A5 true JP2024516172A5 (enExample) | 2025-05-01 |
Family
ID=81585202
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564582A Pending JP2024516172A (ja) | 2021-04-23 | 2022-04-22 | 間葉系前駆体又は幹細胞を使用する急性呼吸窮迫症候群（ａｒｄｓ）を治療するための方法 |
| JP2023564584A Pending JP2024516173A (ja) | 2021-04-23 | 2022-04-22 | 間葉系前駆体又は幹細胞を使用する特定の患者における急性呼吸窮迫症候群（ａｒｄｓ）を治療するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564584A Pending JP2024516173A (ja) | 2021-04-23 | 2022-04-22 | 間葉系前駆体又は幹細胞を使用する特定の患者における急性呼吸窮迫症候群（ａｒｄｓ）を治療するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20240207323A1 (enExample) |
| EP (2) | EP4326295A1 (enExample) |
| JP (2) | JP2024516172A (enExample) |
| KR (2) | KR20240001172A (enExample) |
| AU (2) | AU2022260822A1 (enExample) |
| BR (2) | BR112023021840A2 (enExample) |
| CA (2) | CA3216129A1 (enExample) |
| WO (2) | WO2022224206A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4663241A3 (en) | 2010-10-08 | 2026-03-25 | Mesoblast International Sàrl | Enhanced msc preparations |
| AU2018372631B2 (en) | 2017-11-22 | 2025-06-05 | Mesoblast International Sarl | Cellular compositions and methods of treatment I |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5486359A (en) | 1990-11-16 | 1996-01-23 | Osiris Therapeutics, Inc. | Human mesenchymal stem cells |
| US6251295B1 (en) | 1998-01-08 | 2001-06-26 | Nexell Therapeutics Inc. | Method for recirculation washing of blood cells |
| MX2021014742A (es) * | 2019-06-05 | 2022-02-11 | Univ Emory | Peptidomimeticos para el tratamiento de infecciones por coronavirus y picornavirus. |
-
2022
- 2022-04-22 AU AU2022260822A patent/AU2022260822A1/en active Pending
- 2022-04-22 US US18/556,845 patent/US20240207323A1/en active Pending
- 2022-04-22 BR BR112023021840A patent/BR112023021840A2/pt unknown
- 2022-04-22 JP JP2023564582A patent/JP2024516172A/ja active Pending
- 2022-04-22 AU AU2022261504A patent/AU2022261504A1/en active Pending
- 2022-04-22 KR KR1020237039592A patent/KR20240001172A/ko active Pending
- 2022-04-22 US US18/556,827 patent/US20240197787A1/en active Pending
- 2022-04-22 BR BR112023021825A patent/BR112023021825A2/pt unknown
- 2022-04-22 JP JP2023564584A patent/JP2024516173A/ja active Pending
- 2022-04-22 WO PCT/IB2022/053762 patent/WO2022224206A1/en not_active Ceased
- 2022-04-22 CA CA3216129A patent/CA3216129A1/en active Pending
- 2022-04-22 EP EP22724876.2A patent/EP4326295A1/en active Pending
- 2022-04-22 KR KR1020237039593A patent/KR20240001173A/ko active Pending
- 2022-04-22 WO PCT/IB2022/053763 patent/WO2022224207A1/en not_active Ceased
- 2022-04-22 CA CA3216121A patent/CA3216121A1/en active Pending
- 2022-04-22 EP EP22721854.2A patent/EP4326294A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023520233A5 (enExample) | ||
| Cepkova et al. | Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome | |
| Ziemka-Nalecz et al. | Insights into the neuroinflammatory responses after neonatal hypoxia-ischemia | |
| Liu et al. | Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study | |
| Sawa et al. | Attenuation of cardiopulmonary bypass–derived inflammatory reactions reduces myocardial reperfusion injury in cardiac operations | |
| Lim et al. | Association of stress during delivery with increased numbers of nucleated cells and hematopoietic progenitor cells in umbilical cord blood | |
| Takano et al. | Pleiotropic effects of cytokines on acute myocardial infarction: G-CSF as a novel therapy for acute myocardial infarction | |
| Hirschl et al. | Severe myocardial dysfunction during extracorporeal membrane oxygenation | |
| JP2018184448A5 (enExample) | ||
| JP2012510521A5 (enExample) | ||
| JP2017141230A5 (enExample) | ||
| JP2019535677A5 (enExample) | ||
| Lamas et al. | Human endothelial cells prolong eosinophil survival. Regulation by cytokines and glucocorticoids. | |
| Babajani et al. | Human placenta-derived amniotic epithelial cells as a new therapeutic hope for COVID-19-associated acute respiratory distress syndrome (ARDS) and systemic inflammation | |
| JP2024516173A5 (enExample) | ||
| JP2023513847A5 (enExample) | ||
| Wang et al. | Allogeneic stem cell transplantation combined with transfusion of mesenchymal stem cells in primary myelofibrosis: a multicenter retrospective study | |
| Ma et al. | Low-dose post-transplant cyclophosphamide with G-CSF/ATG based haploidentical protocol provides favorable outcomes for SAA patients | |
| CN116406277A (zh) | 治疗急性呼吸道炎症病症和细胞因子风暴综合征的方法 | |
| JP2024500698A5 (enExample) | ||
| Papait et al. | Perinatal cells: A promising COVID-19 therapy? | |
| Yewei et al. | Study of the mechanism of pulmonary protection strategy on pulmonary injury with deep hypothermia low flow. | |
| Mullins et al. | COVID-19 and placental infection: are fetal survivors at risk of long-term cardiovascular complications? | |
| Nova-Lamperti et al. | Vascular Regeneration by Endothelial Progenitor Cells | |
| Tao et al. | Improvement of monocyte secretion function in a porcine pancreatitis model by continuous dose-dependent veno-venous hemofiltration |